We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.
In Nature Communications, the Lehner lab compare genome-wide CRISPR/Cas9-mediated forward genetic screens with gene-trap mutagenesis screens in haploid human cells, identifying new factors that control mammalian ER-associated degradation of MHC class I molecules.
In Traffic, the Deane lab have revealed a new cell biological framework for pathogenesis of the fatal neurodegenerative disorder Krabbe Disease, by characterizing a series of disease mutations in the lysosomal enzyme galactocerebrosidase (GALC).
A new collaboration between the Lehner lab and GSK, part of their Discovery Partnerships with Academia (DPAc) initiative, will aim to develop and commercialise new treatments for HIV that target latent virus.